tradingkey.logo

Sol Gel Technologies Ltd

SLGL
61.100USD
-4.680-7.11%
交易中 美东报价延迟15分钟
170.21M总市值
亏损市盈率 TTM

Sol Gel Technologies Ltd

61.100
-4.680-7.11%

关于 Sol Gel Technologies Ltd 公司

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

Sol Gel Technologies Ltd简介

公司代码SLGL
公司名称Sol Gel Technologies Ltd
上市日期Feb 01, 2018
CEO- -
员工数量34
证券类型Ordinary Share
年结日Feb 01
公司地址Golda Meir 7
城市NESS-ZIONA
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Israel
邮编- -
电话97289313433
网址http://www.sol-gel.com
公司代码SLGL
上市日期Feb 01, 2018
CEO- -

Sol Gel Technologies Ltd公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
+105123.00%
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Dr. Itzik Yosef, Ph.D.
Dr. Itzik Yosef, Ph.D.
Vice President - Operations
Vice President - Operations
--
--
Dr. Dubi (Dov) Zamir, Ph.D.
Dr. Dubi (Dov) Zamir, Ph.D.
Vice President - Special Projects
Vice President - Special Projects
--
--
Mr. Itai Arkin
Mr. Itai Arkin
Director
Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Ms. Hani Lerman
Ms. Hani Lerman
Director
Director
--
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
+105123.00%
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Dr. Itzik Yosef, Ph.D.
Dr. Itzik Yosef, Ph.D.
Vice President - Operations
Vice President - Operations
--
--
Dr. Dubi (Dov) Zamir, Ph.D.
Dr. Dubi (Dov) Zamir, Ph.D.
Vice President - Special Projects
Vice President - Special Projects
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 2月6日 周五
更新时间: 2月6日 周五
持股股东
股东类型
持股股东
持股股东
占比
M.Arkin Dermatology, Ltd.
64.86%
Opaleye Management Inc.
13.78%
Phoenix Investment and Finances Ltd
7.83%
Arkin (Moshe)
5.14%
Yelin Lapidot Provident Funds Management Ltd
0.64%
其他
7.75%
持股股东
持股股东
占比
M.Arkin Dermatology, Ltd.
64.86%
Opaleye Management Inc.
13.78%
Phoenix Investment and Finances Ltd
7.83%
Arkin (Moshe)
5.14%
Yelin Lapidot Provident Funds Management Ltd
0.64%
其他
7.75%
股东类型
持股股东
占比
Corporation
64.86%
Hedge Fund
13.78%
Investment Advisor
8.54%
Individual Investor
5.14%
Insurance Company
0.27%
Research Firm
0.16%
Investment Advisor/Hedge Fund
0.05%
其他
7.20%

机构持股

更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
35
634.85K
22.79%
-440.31K
2025Q3
35
286.02K
10.27%
-480.14K
2025Q2
36
2.50M
89.88%
-104.83K
2025Q1
37
2.45M
84.60%
+78.00K
2024Q4
35
23.50M
84.37%
-314.30K
2024Q3
34
23.55M
84.52%
-115.49K
2024Q2
31
25.52M
91.61%
+1.51M
2024Q1
30
23.87M
85.67%
+1.61M
2023Q4
31
22.12M
83.66%
-222.95K
2023Q3
30
22.20M
83.99%
-4.35K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
M.Arkin Dermatology, Ltd.
1.81M
64.86%
--
--
Jun 11, 2025
Opaleye Management Inc.
383.58K
13.77%
+10.43K
+2.80%
Dec 17, 2025
Phoenix Investment and Finances Ltd
218.22K
7.83%
-28.80K
-11.66%
Sep 30, 2025
Arkin (Moshe)
143.26K
5.14%
+105.12K
+275.67%
Jun 11, 2025
Menora Mivtachim Insurance Ltd.
7.61K
0.27%
+7.61K
--
Sep 30, 2025
Morgan Stanley & Co. LLC
4.37K
0.16%
-970.00
-18.18%
Sep 30, 2025
Steward Partners Investment Advisory, LLC
316.00
0.01%
--
--
Sep 30, 2025
查看更多

持股ETF

更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
除权除息日
类型
比率
May 01, 2025
Merger
10→1
公告日期
除权除息日
类型
比率
May 01, 2025
Merger
10→1
KeyAI